Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan - Report - MDSpire
Advertisement
Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan
Clinical Report: Postmarketing Evaluation of Elobixibat in Japanese Patients
Overview
This study evaluates the safety and effectiveness of elobixibat in treating chronic constipation among Japanese patients with schizophrenia or depression. Results indicate significant improvements in defecation frequency and stool consistency without serious adverse drug reactions.
Background
Chronic constipation is a prevalent gastrointestinal disorder that significantly impacts the quality of life, particularly in patients with psychiatric conditions such as schizophrenia and depression. These patients often experience constipation due to the side effects of medications, making effective treatment essential. Elobixibat, a novel laxative, offers a potential therapeutic option by targeting the underlying mechanisms of constipation.
Data Highlights
Group
Baseline Defecation Frequency
Week 4 Defecation Frequency
Week 52 Defecation Frequency
ADRs (%)
Schizophrenia (4-week)
3.3
5.3
N/A
4.76
Depression (4-week)
3.0
4.9
N/A
3.88
Schizophrenia (52-week)
N/A
N/A
Higher than baseline
2.33
Depression (52-week)
N/A
N/A
Higher than baseline
9.09
Key Findings
Elobixibat improved defecation frequency significantly in both schizophrenia and depression groups.
Mean defecation frequency increased from 3.3 to 5.3 in schizophrenia patients and from 3.0 to 4.9 in depression patients after 4 weeks.
Approximately 60% of patients achieved an ideal Bristol Stool Form Scale score of 4 by week 52.
Adverse drug reactions were low, with diarrhea being the most common, affecting 4.76% of schizophrenia patients and 3.88% of depression patients in the 4-week group.
No serious adverse drug reactions were reported during the study period.
Clinical Implications
The findings suggest that elobixibat is a safe and effective treatment option for chronic constipation in patients with schizophrenia or depression. Clinicians should consider this medication for patients experiencing constipation related to psychiatric conditions, particularly given its favorable safety profile.
Conclusion
Elobixibat demonstrates significant efficacy in managing chronic constipation in patients with schizophrenia and depression, with a reassuring safety profile. These results support its use in clinical practice for this patient population.
